BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vasudevan A, Gibson PR, Langenberg DRV. Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told? World J Gastroenterol 2017; 23(35): 6385-6402 [PMID: 29085188 DOI: 10.3748/wjg.v23.i35.6385] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 15] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Xu Y, Sharma A, Chen Y, Zhou H. What We Can Learn from Current Inflammatory Bowel Disease (IBD) Biological Therapy—Dose Regimen and Others. Curr Pharmacol Rep 2019;5:115-30. [DOI: 10.1007/s40495-019-00180-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Ma C, Lee JK, Mitra AR, Teriaky A, Choudhary D, Nguyen TM, Vande Casteele N, Khanna R, Panaccione R, Feagan BG, Jairath V. Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Aliment Pharmacol Ther 2019;50:5-23. [DOI: 10.1111/apt.15297] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
3 Kayal M, Shah S. Ulcerative Colitis: Current and Emerging Treatment Strategies. J Clin Med 2019;9:E94. [PMID: 31905945 DOI: 10.3390/jcm9010094] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
4 Con D, Parthasarathy N, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley DJ, Sparrow MP, Gibson PR, van Langenberg DR, Vasudevan A. Development of a Simple, Serum Biomarker-based Model Predictive of the Need for Early Biologic Therapy in Crohn's Disease.J Crohns Colitis. 2021;15:583-593. [PMID: 32949458 DOI: 10.1093/ecco-jcc/jjaa194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Bonnaud G, Bouhnik Y, Hagege H, Hebuterne X, Pariente B, Roblin X, Peyrin-Biroulet L. Monitoring of inflammatory bowel disease in 2019: A French consensus for clinical practice. Dig Liver Dis 2020;52:704-20. [PMID: 32402743 DOI: 10.1016/j.dld.2020.03.033] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Pouillon L, Van Stappen J, Bossuyt P, Danese S, Peyrin-biroulet L. Should we use anti-tumor necrosis factor agents or vedolizumab as first-line biological therapy in ulcerative colitis? Best Practice & Research Clinical Gastroenterology 2018;32-33:17-25. [DOI: 10.1016/j.bpg.2018.05.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
7 Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther 2022;55:1320-9. [PMID: 35218038 DOI: 10.1111/apt.16817] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Panés J, Gisbert JP. Eficacia de tofacitinib en el tratamiento de la colitis ulcerosa. Gastroenterología y Hepatología 2019;42:403-12. [DOI: 10.1016/j.gastrohep.2019.03.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Narula N, Wong ECL, Dulai PS, Sengupta NK, Marshall JK, Colombel JF, Reinisch W. Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00394-3. [PMID: 33838348 DOI: 10.1016/j.cgh.2021.04.006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Lenti MV, Dolby V, Clark T, Hall V, Tattersall S, Fairhurst F, Kenneth C, Walker R, Kemp K, Borg-Bartolo S, Limdi JK, Taylor J, Townsend T, Subramanian S, Storey D, Assadsangabi A, Stansfield C, Smith P, Byrne D, De Silvestri A, Selinger CP. A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study II. Aliment Pharmacol Ther 2021. [PMID: 34935160 DOI: 10.1111/apt.16742] [Reference Citation Analysis]
11 Zhu P, Sun JF, Gu YF, Chen HJ, Xu MM, Li YR, Yang BL. Combined therapy with early initiation of infliximab following drainage of perianal fistulising Crohn's disease: a retrospective cohort study. BMC Gastroenterol 2022;22:15. [PMID: 35012467 DOI: 10.1186/s12876-021-02078-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ghafouri Z, Seyyedian S, Nikbakht J, Kouhsari E, Bayat S, Zargar H, Houshmand G. Effect of Sodium Cromoglycate on Acetic Acid-induced Ulcerative Colitis in Mice. Korean J Gastroenterol 2020;75:39-45. [PMID: 31986572 DOI: 10.4166/kjg.2020.75.1.39] [Reference Citation Analysis]
13 Mountifield R. Anti-tumor necrosis factors (TNFs) are outdated-It's time to move on: Session three summary. J Gastroenterol Hepatol 2021;36 Suppl 1:25-6. [PMID: 33817852 DOI: 10.1111/jgh.15455] [Reference Citation Analysis]
14 Sun XL, Chen SY, Tao SS, Qiao LC, Chen HJ, Yang BL. Optimized timing of using infliximab in perianal fistulizing Crohn's disease. World J Gastroenterol 2020; 26(14): 1554-1563 [PMID: 32327905 DOI: 10.3748/wjg.v26.i14.1554] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Lim HS, Kim SK, Hong SJ. Food Elimination Diet and Nutritional Deficiency in Patients with Inflammatory Bowel Disease. Clin Nutr Res. 2018;7:48-55. [PMID: 29423389 DOI: 10.7762/cnr.2018.7.1.48] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
16 Singh A, Mahajan R, Kedia S, Dutta AK, Anand A, Bernstein CN, Desai D, Pai CG, Makharia G, Tevethia HV, Mak JW, Kaur K, Peddi K, Ranjan MK, Arkkila P, Kochhar R, Banerjee R, Sinha SK, Ng SC, Hanauer S, Verma S, Dutta U, Midha V, Mehta V, Ahuja V, Sood A. Use of thiopurines in inflammatory bowel disease: an update. Intest Res 2022;20:11-30. [PMID: 33845546 DOI: 10.5217/ir.2020.00155] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
17 Sassine S, Zekhnine S, Qaddouri M, Djani L, Cambron-Asselin C, Savoie-Robichaud M, Lin YF, Grzywacz K, Groleau V, Dirks M, Drouin É, Halac U, Marchand V, Girard C, Courbette O, Patey N, Dal Soglio D, Deslandres C, Jantchou P. Factors associated with time to clinical remission in pediatric luminal Crohn's disease: A retrospective cohort study. JGH Open 2021;5:1373-81. [PMID: 34950781 DOI: 10.1002/jgh3.12684] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Smith RL, Taylor KM, Friedman AB, Gibson DJ, Con D, Gibson PR. Early sonographic response to a new medical therapy is associated with future treatment response or failure in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2022;34:613-21. [PMID: 35352696 DOI: 10.1097/MEG.0000000000002367] [Reference Citation Analysis]
19 Sigall Boneh R, Van Limbergen J, Wine E, Assa A, Shaoul R, Milman P, Cohen S, Kori M, Peleg S, On A, Shamaly H, Abramas L, Levine A. Dietary Therapies Induce Rapid Response and Remission in Pediatric Patients With Active Crohn's Disease. Clin Gastroenterol Hepatol 2021;19:752-9. [PMID: 32302709 DOI: 10.1016/j.cgh.2020.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
20 Norton B, Sullivan A, Senior J, Candela N, Jason M, Weyant K. Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2021.12.001] [Reference Citation Analysis]
21 Han Z, Shi L. Long non-coding RNA LUCAT1 modulates methotrexate resistance in osteosarcoma via miR-200c/ABCB1 axis. Biochemical and Biophysical Research Communications 2018;495:947-53. [DOI: 10.1016/j.bbrc.2017.11.121] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 16.3] [Reference Citation Analysis]
22 Ashton JJ, Beattie RM. Treatment of Active Crohn’s Disease With an Ordinary Food-Based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology 2019;157:1160-1. [DOI: 10.1053/j.gastro.2019.01.277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Hanžel J, Sedano R, Jeyarajah J, Zou G, McFarlane SC, Ma C, Jairath V. Similar Clinical Improvement Rates Among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression. Inflamm Bowel Dis 2022:izac018. [PMID: 35166778 DOI: 10.1093/ibd/izac018] [Reference Citation Analysis]
24 Sorrentino D, Nguyen VQ, Love K. Fecal Lactoferrin Predicts Primary Nonresponse to Biologic Agents in Inflammatory Bowel Disease. Dig Dis 2021;39:626-33. [PMID: 33631768 DOI: 10.1159/000515432] [Reference Citation Analysis]
25 Cassinotti A, Batticciotto A, Parravicini M, Lombardo M, Radice P, Cortelezzi CC, Segato S, Zanzi F, Cappelli A, Segato S. Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications. Therap Adv Gastroenterol 2022;15:17562848221085889. [PMID: 35340755 DOI: 10.1177/17562848221085889] [Reference Citation Analysis]
26 Armuzzi A, Avedano L, Greveson K, Kang T. Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies. J Crohns Colitis 2019;13:259-66. [PMID: 30285235 DOI: 10.1093/ecco-jcc/jjy150] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]